Filter Results:
(924)
Show Results For
- All HBS Web
(1,279)
- People (5)
- News (171)
- Research (924)
- Events (6)
- Multimedia (12)
- Faculty Publications (757)
Show Results For
- All HBS Web
(1,279)
- People (5)
- News (171)
- Research (924)
- Events (6)
- Multimedia (12)
- Faculty Publications (757)
Sort by
- September 2019
- Case
Dementia Discovery Fund
By: Richard G. Hamermesh, Kathy Giusti and Sarah Gulick
The case is set in March 2019, and tells the story of the founding of the Dementia Discovery Fund (DDF). The idea for the fund began in 2015, when then-Prime Minister David Cameron spoke about the importance of making breakthroughs in dementia research, and pledged... View Details
Keywords: Venture Capital; Investment Funds; Mission and Purpose; Recruitment; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry; Boston; Massachusetts; London; England
Hamermesh, Richard G., Kathy Giusti, and Sarah Gulick. "Dementia Discovery Fund." Harvard Business School Case 820-045, September 2019.
- December 1999 (Revised February 2001)
- Case
CVS: The Web Strategy
By: John A. Deighton and Anjali C. Shah
How should America's second-largest pharmacy chain respond to the challenge from online drugstores? What threat does the web pose to bricks and mortar distribution of prescription drugs and the other items that make up 50% of a drugstore's sales? This case describes... View Details
Keywords: Leveraged Buyouts; Marketing Channels; Distribution Channels; Service Operations; Corporate Strategy; Pharmaceutical Industry; Pharmaceutical Industry
Deighton, John A., and Anjali C. Shah. "CVS: The Web Strategy." Harvard Business School Case 500-008, December 1999. (Revised February 2001.) (request a courtesy copy.)
- 02 Oct 2000
- Research & Ideas
The Dubious Logic of Global Megamergers
with their mega-deals, you can exploit that fact to improve your own competitive position. For instance, while pharmaceutical players such as Glaxo Wellcome and SmithKline Beecham have made headlines with their merger news, one large... View Details
Keywords: by Pankaj Ghemawat & Fariborz Ghadar
- 25 Oct 2016
- First Look
October 25, 2016
https://www.hbs.edu/faculty/Pages/item.aspx?num=51759 forthcoming American Economic Journal: Economic Policy When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization By: Dafny, Leemore S., Christopher Ody, and Matt Schmitt Abstract—Branded View Details
Keywords: Sean Silverthorne
- 02 Jul 2001
- Research & Ideas
Ray A. Goldberg
is the blurring of agriculture and pharmaceuticals limited to seeds and plants. Animals are being turned into drug-manufacturing facilities" as well. Thus, Goldberg says, bioengineering may some day lead to animals whose milk, for... View Details
- 14 Dec 2010
- First Look
First Look: Dec. 14
addresses a decision to replace salesmen netbook PCs with iPhones, including converting the company's sales and customer applications to the iPhone platform. Purchase this case:http://cb.hbsp.harvard.edu/cb/product/911413-PDF-ENG Hikma View Details
Keywords: Sean Silverthorne
- 02 Mar 2010
- First Look
First Look: March 2
innovation in a wide range of other industries, including pharmaceuticals and biotechnology, IT and telecommunications, defense, chemicals, and agriculture. We believe that there are valuable lessons in this research for the energy... View Details
Keywords: Martha Lagace
- May 2025 (Revised June 2025)
- Supplement
Michael Ku and Global Clinical Supply at Pfizer Inc.: Bringing Hope to Patients (D)
By: Linda A. Hill and Lydia Begag
This fourth installment in the Pfizer Global Clinical Supply (GCS) transformation case series highlights how over a decade of cultural and digital evolution positioned GCS to meet unprecedented global challenges. In 2011, Michael Ku became the Vice President of GCS and... View Details
Keywords: Innovation Leadership; Technological Innovation; Leadership Development; Leadership Style; Research and Development; Science-Based Business; Transformation; Health Pandemics; AI and Machine Learning; Analytics and Data Science; Digital Transformation; Leading Change; Product Launch; Supply Chain; Organizational Change and Adaptation; Alignment; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States; Asia; Europe; Latin America
Hill, Linda A., and Lydia Begag. "Michael Ku and Global Clinical Supply at Pfizer Inc.: Bringing Hope to Patients (D)." Harvard Business School Supplement 425-079, May 2025. (Revised June 2025.)
- April 2025
- Case
Radical Transformation at Bayer: Dynamic Shared Ownership
By: Boris Groysberg and Gamze Yucaoglu
In 2023, Bill Anderson became CEO of Bayer AG, a 160-year-old life sciences giant looking to strengthen its pharma pipeline, manage debt, and cut through bureaucracy. His bold response: Dynamic Shared Ownership (DSO), a radical model replacing traditional hierarchies... View Details
Keywords: Human Resources; Business Strategy; Alignment; Innovation and Management; Organizational Structure; Pharmaceutical Industry; Pharmaceutical Industry
Groysberg, Boris, and Gamze Yucaoglu. "Radical Transformation at Bayer: Dynamic Shared Ownership." Harvard Business School Case 425-061, April 2025.
- 2001
- Other Unpublished Work
Clusters of Innovation Initiative: San Diego
The study contains a conceptual framework for assessing the competitiveness of regional economies, an analysis of the San Diego region overall, as well as detailed assessments of two representative clusters—biotechnology/pharmaceuticals and communications. The report... View Details
Keywords: Clusters; Economics; Industry Clusters; Economy; Growth and Development; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; San Diego
Porter, Michael E. "Clusters of Innovation Initiative: San Diego." Council on Competitiveness, Washington, DC, May 2001. (Report.)
- 2014
- Working Paper
Bio-Piracy or Prospering Together? Fuzzy Set and Qualitative Analysis of Herbal Patenting by Firms
By: Prithwiraj Choudhury and Tarun Khanna
Since the 1990s, several Western firms have filed patents based on medicinal herbs from emerging markets, evoking protests from local stakeholders against 'bio-piracy'. We explore conditions under which firms and local stakeholders share rents from such patents. Our... View Details
Keywords: Rents From New Technology; Local Stakeholders; Herbal Patents; QCA; Fuzzy Set Analysis; Qualitative Case Studies; Plant-Based Agribusiness; Patents; Emerging Markets; Health Care and Treatment; Business and Stakeholder Relations; Cross-Cultural and Cross-Border Issues; Pharmaceutical Industry; Pharmaceutical Industry
Choudhury, Prithwiraj, and Tarun Khanna. "Bio-Piracy or Prospering Together? Fuzzy Set and Qualitative Analysis of Herbal Patenting by Firms." Harvard Business School Working Paper, No. 14-081, February 2014.
- September 1996
- Case
Food and Drug Administration: Business as Unusual at CDER
By: Steven C. Wheelwright and James Leonard
Wheelwright, Steven C., and James Leonard. "Food and Drug Administration: Business as Unusual at CDER." Harvard Business School Case 697-022, September 1996.
- November 1998
- Case
Wegmans Food Markets: Diabetes Counseling
By: Ray A. Goldberg, David E. Bell and Ann Leamon
Danny Wegman, president of Wegmans Food Markets, is trying to decide how to evaluate the success of a nutrition-counseling program for diabetics, and whether and how to expand the program beyond the two stores currently involved. Wegmans, with 57 stores and $2.3... View Details
Keywords: Performance Evaluation; Expansion; Programs; Human Needs; Financial Management; Health Care and Treatment; Nutrition; Consumer Behavior; Pharmaceutical Industry; Pharmaceutical Industry
Goldberg, Ray A., David E. Bell, and Ann Leamon. "Wegmans Food Markets: Diabetes Counseling." Harvard Business School Case 599-057, November 1998.
- 16 Oct 2007
- First Look
First Look: October 16, 2007
this case: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=508036 Michael Fernandes at Nicholas Piramal Harvard Business School Case 408-001 Michael Fernandes, the Director of Custom Manufacturing Operations at the View Details
Keywords: Sean Silverthorne
- 15 Feb 2000
- Research & Ideas
The Right Connections
pharmaceutical companies — what the authors call downstream social capital — had a direct impact on the size of the startup's IPO. "Downstream social capital was essential in attracting the interest of a top investment bank and... View Details
Keywords: by Judith A. Ross
- July 2013 (Revised November 2021)
- Module Note
Exploration vs. Exploitation
By: Willy Shih
This module note introduces James March's concept of exploration and exploitation, and the management challenge of balancing the allocation of resources to the two activities in the firm. The note also touches on the O'Reilly and Tushman paper on the ambidextrous... View Details
Keywords: Exploration And Exploitation; Exploitation; Research; Scientific Research; Product Commercialization; Innovation and Invention; Innovation and Management; Innovation Leadership; Innovation Strategy; Technological Innovation; Knowledge Acquisition; Growth and Development Strategy; Resource Allocation; Strategic Planning; Research and Development; Science-Based Business; Corporate Strategy; Knowledge Sharing; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States
Shih, Willy. "Exploration vs. Exploitation." Harvard Business School Module Note 614-004, July 2013. (Revised November 2021.)
- 10 Sep 2007
- Research & Ideas
High Note: Managing the Medici String Quartet
The panel consisted of Bob Frosch, who used to head NASA and R&D for GM; Vicki Sato, who was president of Vertex Pharmaceuticals and is now on the HBS faculty; and Peter Hanke, a conductor. These people have had a lot of experience... View Details
- 04 Apr 2022
- Research & Ideas
Tech Hubs: How Software Brought Talent and Prosperity to New Cities
period. Software is penetrating other industries, Kerr notes. Take vaccines. Pharmaceutical companies’ speedy development of mRNA-based vaccines for COVID-19 required software, he notes. “Their capacity to bring a substantial software, AI... View Details
Keywords: by Rachel Layne
- 06 Jun 2017
- First Look
First Look at New Research and Ideas: June 6, 2017
regulatory pathway, the biosimilars pathway, on the strategy of a major pharmaceutical firm that finds its largest product (60% of revenue) at risk. The case reviews the rationale for the pathway, the emerging biosimilars market entrants,... View Details
Keywords: Sean Silverthorne
- 11 Nov 2015
- Working Paper Summaries